



## Medical Policy Manual

## Draft Revision Policy: Do Not Implement

### Fam-trastuzumab Deruxtecan-nxki (Enhertu®)

#### IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

**The proposal is to add text/statements in red and to delete text/statements with strikethrough:  
POLICY**

#### INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

###### **HER2-Positive Metastatic Breast Cancer**

Enhertu, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive [immunohistochemistry score (IHC) 3+ or in situ hybridization test (ISH) +] breast cancer who have received a prior anti-HER2 based regimen either: in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.

Enhertu, in combination with pertuzumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH +) breast cancer as determined by an FDA-approved test.

###### **HER2-Low and HER2-Ultralow Metastatic Breast Cancer**

**Enhertu is indicated for the treatment of adult patients with unresectable or metastatic**

- Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-low [immunohistochemistry score (IHC) 1+ or IHC 2+/ISH-) in situ hybridization test (ISH) negative] breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
- Enhertu is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.

###### **Gastric or Gastroesophageal Junction Adenocarcinoma**

**Enhertu is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.**

###### **HER2- Mutant Unresectable or Metastatic Non-Small Cell Lung Cancer (NSCLC)**

Enhertu is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.

###### **HER2-Positive Locally Advanced or Metastatic Gastric Cancer**



## Medical Policy Manual

## Draft Revision Policy: Do Not Implement

Enhertu is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

### HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors

Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

#### Compendial Uses

- HER2-positive breast cancer, treatment of recurrent disease
- HER2-low and ultralow breast cancer, treatment of recurrent disease
- Non-small cell lung cancer with HER2 mutations, treatment of recurrent and advanced disease
- ~~HER2-amplified colorectal cancer (including appendiceal and anal adenocarcinoma)~~
- HER2-positive esophageal, gastric or gastroesophageal junction cancer
- HER2-positive solid tumors
  - HER2-amplified colorectal cancer (including appendiceal and anal adenocarcinoma)
  - HER2-positive cervical cancer
  - HER2-positive endometrial carcinoma
  - ~~HER2-positive salivary gland tumor~~
  - HER2-positive ovarian cancer
  - HER2-positive vaginal cancer
  - **HER2-positive vulvar cancer**
  - HER2-positive ampullary adenocarcinoma
  - HER2-positive salivary gland tumor
  - HER2-positive pancreatic adenocarcinoma
  - HER2-amplified small bowel adenocarcinoma
  - HER2-positive occult primary
  - HER2-positive appendiceal neoplasms and cancers
  - HER2-positive bladder cancer
  - HER2-positive biliary tract cancer
  - ~~HER2-positive solid tumors~~

All other indications are considered experimental/investigational and not medically necessary.

#### **DOCUMENTATION**

Submission of the following information is necessary to initiate the prior authorization review: human epidermal growth factor receptor 2 (HER2) status (e.g., immunohistochemistry (IHC) score, in situ hybridization (ISH) test) and hormone receptor (HR) status.

#### **COVERAGE CRITERIA**

##### **Breast Cancer**

Authorization of 12 months may be granted for treatment of breast cancer when **any** either of the following criteria are met:

- Member has HER2-positive breast cancer and meets **either** all of the following criteria:
  - ~~The disease had no response to preoperative systemic therapy, or the disease is recurrent, metastatic, or unresectable~~



## Medical Policy Manual

## Draft Revision Policy: Do Not Implement

- The requested medication will be used as a single agent when the disease had no response to preoperative systemic therapy, or the disease is recurrent, metastatic, or unresectable.
- The requested medication will be used in combination with pertuzumab as first line treatment of unresectable or metastatic disease.
- Member has HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer and meets all of the following criteria:
  - The disease had no response to preoperative systemic therapy, or the disease is recurrent, metastatic or unresectable.
  - The requested medication will be used as a single agent.
- Member has HER2-ultralow (IHC 0 with membrane staining) breast cancer and meets all of the following criteria:
  - The disease is recurrent metastatic or unresectable.
  - The disease is hormone receptor positive with visceral crisis or endocrine therapy refractory or the disease is hormone receptor negative.
  - The requested medication will be used as a single agent.
- Member has HER2-negative breast cancer and meets all of the following criteria:
  - The disease had no response to preoperative systemic therapy, or the disease is recurrent unresectable or metastatic.
  - The disease is hormone receptor positive with visceral crisis or endocrine therapy refractory.
  - The requested medication will be used as a single agent.
  - The requested medication will be used for first-line therapy.

### Non-Small Cell Lung Cancer

Authorization of 12 months may be granted for subsequent ~~therapy~~ treatment of non-small cell lung cancer with HER2 (ERBB2) mutations or ~~HER2 overexpression (IHC 3+)~~ when all of the following criteria are met:

- The disease is recurrent, advanced, metastatic or unresectable.
- The requested medication will be used as a single agent.
- The member has not experienced disease progression on a HER2 targeted drug (e.g., ~~Enhertu, Kadcyla~~).

### Colorectal Cancer

Authorization of 12 months may be granted for treatment of colorectal cancer (including appendiceal and anal adenocarcinoma) with ~~HER2 amplified disease as a single agent when the requested medication will be used as subsequent therapy for progression of advanced or metastatic disease~~.

### Esophageal, Gastric or Gastroesophageal Junction Adenocarcinoma

Authorization of 12 months may be granted for members with HER2-positive disease who are not surgical candidates or for subsequent treatment of HER2-positive ~~unresectable~~ locally advanced, recurrent or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma as a single agent.

### Cervical Cancer

Authorization of 12 months may be granted for ~~subsequent treatment of recurrent or metastatic HER2-positive (IHC 3+ or 2+) cervical cancer when used as a single agent~~.

### Endometrial Carcinoma

Authorization of 12 months may be granted for ~~subsequent treatment of recurrent HER2-positive (IHC 3+ or 2+) endometrial carcinoma when used as a single agent~~.



## Medical Policy Manual

## Draft Revision Policy: Do Not Implement

### **Salivary Gland Tumor**

~~Authorization of 12 months may be granted for treatment of recurrent, unresectable or metastatic HER2-positive salivary gland tumor when used as a single agent.~~

### **Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer**

~~Authorization of 12 months may be granted for treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer when all of the following criteria are met:~~

- ~~• The member has platinum-resistant persistent or recurrent disease~~
- ~~• The disease is HER2-positive (IHC 3+ or 2+)~~
- ~~• The requested medication will be used as a single agent~~

### **Solid Tumors**

~~Authorization of 12 months may be granted for treatment of solid tumors when all of the following criteria are met:~~

- ~~• The disease is unresectable, metastatic, advanced, recurrent, or persistent.~~
- ~~• The tumor is HER2-positive (IHC 3+ or 2+).~~
- ~~• The member received prior systemic treatment and has no satisfactory alternative treatment options.~~
- ~~• The requested medication will be used as a single agent.~~

### **Vaginal Cancer**

~~Authorization of 12 months may be granted for subsequent treatment of recurrent or metastatic HER2-positive (IHC 3+ or 2+) vaginal cancer when used as a single agent.~~

### **Biliary Tract Cancer**

~~Authorization of 12 months may be granted for subsequent treatment of unresectable or resected gross residual (R2) disease or metastatic HER2-positive (IHC 3+) biliary tract cancer (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer) when used as a single agent.~~

### **CONTINUATION OF THERAPY**

~~Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.~~

### **MEDICATION QUANTITY LIMITS**

<b>Drug Name</b>	<b>Diagnosis</b>	<b>Maximum Dosing Regimen</b>
Enhertu (Fam-trastuzumab deruxtecan-nxki)	Breast Cancer	Route of Administration: Intravenous 5.4mg/kg every 3 weeks
Enhertu (Fam-trastuzumab deruxtecan-nxki)	Cervical Cancer	Route of Administration: Intravenous 5.4mg/kg every 3 weeks
Enhertu (Fam-trastuzumab deruxtecan-nxki)	Colorectal Cancer, including Appendiceal Adenocarcinoma and Anal Adenocarcinoma	Route of Administration: Intravenous 5.4mg/kg every 3 weeks



## Medical Policy Manual

## Draft Revision Policy: Do Not Implement

Enhertu (Fam-trastuzumab deruxtecan-nxki)	Endometrial Carcinoma	Route of Administration: Intravenous 5.4mg/kg every 3 weeks
Enhertu (Fam-trastuzumab deruxtecan-nxki)	Esophageal, Gastric or Gastroesophageal Junction Adenocarcinoma	Route of Administration: Intravenous 6.4mg/kg every 3 weeks
Enhertu (Fam-trastuzumab deruxtecan-nxki)	Hepatobiliary Cancer, including Cholangiocarcinoma or Gallbladder Cancer	Route of Administration: Intravenous 5.4mg/kg every 3 weeks
Enhertu (Fam-trastuzumab deruxtecan-nxki)	Non-Small Cell Lung Cancer (NSCLC)	Route of Administration: Intravenous 5.4mg/kg every 3 weeks
Enhertu (Fam-trastuzumab deruxtecan-nxki)	Ovarian, Fallopian, Primary Peritoneal Cancer	Route of Administration: Intravenous 5.4mg/kg every 3 weeks
Enhertu (Fam-trastuzumab deruxtecan-nxki)	Salivary Gland Tumor	Route of Administration: Intravenous 6.4mg/kg every 3 weeks
Enhertu (Fam-trastuzumab deruxtecan-nxki)	Solid Tumors	Route of Administration: Intravenous 5.4mg/kg every 3 weeks
Enhertu (Fam-trastuzumab deruxtecan-nxki)	Vaginal Cancer	Route of Administration: Intravenous 5.4mg/kg every 3 weeks

### APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

### ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

### REFERENCES

1. Enhertu [package insert]. Basking Ridge, NJ: Daiichi Sankyo Inc.; December 2025.
2. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org>. Accessed December 24, 2025.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Anal Carcinoma. Version 4.2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/anal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf). Accessed September 3, 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/anal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf).
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer. Version 4.2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). Accessed September 3, 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf)
5. National Comprehensive Cancer Network .NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Head and Neck Cancers. Version 5.2025. Available at:



**BlueCross BlueShield  
of Tennessee**

**Policy**

## Medical Policy Manual

## Draft Revision Policy: Do Not Implement

[https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf). Accessed September 3, 2025.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf)

### EFFECTIVE DATE

ID\_CHS\_2025a